Validation of molecular profiling to preoperatively predict aggressive pathologic features in differentiated thyroid cancer.

IF 2.7 2区 医学 Q1 SURGERY
Surgery Pub Date : 2025-10-06 DOI:10.1016/j.surg.2025.109698
Justin Bauzon, Joyce Shin, Gilman Plitt, Rafael Perez-Soto, Michael S Lui, Jee-Hye Choi, Judy Jin, Vikram Krishnamurthy, Eren Berber, Katherine B Heiden, Allan Siperstein, Gustavo Romero-Velez
{"title":"Validation of molecular profiling to preoperatively predict aggressive pathologic features in differentiated thyroid cancer.","authors":"Justin Bauzon, Joyce Shin, Gilman Plitt, Rafael Perez-Soto, Michael S Lui, Jee-Hye Choi, Judy Jin, Vikram Krishnamurthy, Eren Berber, Katherine B Heiden, Allan Siperstein, Gustavo Romero-Velez","doi":"10.1016/j.surg.2025.109698","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The 2015 American Thyroid Association guidelines stratify recurrence risk of differentiated thyroid cancer using pathologic findings. Aggressive features may reclassify tumors as intermediate-to-high risk in patients initially suitable for lobectomy, warranting completion thyroidectomy. Signatures represent distinct patterns of mRNA expression on the basis of molecular pathway features. This study evaluated whether molecular expression profiles (\"signatures\") could preoperatively differentiate high-risk tumors and potentially guide extent of surgery.</p><p><strong>Methods: </strong>Patients who underwent thyroid nodule molecular testing with the Afirma Genomic Sequencing Classifier and subsequent operative resection from 2017 to 2024 were identified. Using features described on surgical pathology, patients were grouped into ATA guideline-based low-risk or intermediate/high-risk cohorts. Among the signatures assessed, Invasion Score was developed to rule out extrathyroidal extension or extensive vascular invasion, whereas Sodium-Iodide Symporter Expression reflects mRNA production levels of the transmembrane glycoprotein involved in thyroid-iodine uptake. Signatures were compared among cohorts using Mann-Whitney U and Kruskal-Wallis tests. Logistic regression was used for multivariate analysis.</p><p><strong>Results: </strong>Of 445 patients analyzed, 366 were low risk and 79 were intermediate/high risk. Among 30 signatures evaluated, expression varied significantly among study cohorts in 23 (77%). Multivariate analysis demonstrated the Invasion Score signature as predictive of greater American Thyroid Association risk classification (odds ratio, 1.3; 95% confidence interval, 1.1-1.5, P = .005) whereas Sodium-Iodide Symporter Expression was protective (odds ratio, 0.78; 95% confidence interval, 0.63-0.94, P = .015).</p><p><strong>Conclusion: </strong>Multiple signature expression profiles showed marked variation among American Thyroid Association risk classes and may help enhance preoperative prognostication. Although Invasion Score mirrors greater risk pathologic features, upregulated Sodium-Iodide Symporter Expression appears to protect from greater American Thyroid Association risk class, although further studies are needed to confirm.</p>","PeriodicalId":22152,"journal":{"name":"Surgery","volume":" ","pages":"109698"},"PeriodicalIF":2.7000,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.surg.2025.109698","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The 2015 American Thyroid Association guidelines stratify recurrence risk of differentiated thyroid cancer using pathologic findings. Aggressive features may reclassify tumors as intermediate-to-high risk in patients initially suitable for lobectomy, warranting completion thyroidectomy. Signatures represent distinct patterns of mRNA expression on the basis of molecular pathway features. This study evaluated whether molecular expression profiles ("signatures") could preoperatively differentiate high-risk tumors and potentially guide extent of surgery.

Methods: Patients who underwent thyroid nodule molecular testing with the Afirma Genomic Sequencing Classifier and subsequent operative resection from 2017 to 2024 were identified. Using features described on surgical pathology, patients were grouped into ATA guideline-based low-risk or intermediate/high-risk cohorts. Among the signatures assessed, Invasion Score was developed to rule out extrathyroidal extension or extensive vascular invasion, whereas Sodium-Iodide Symporter Expression reflects mRNA production levels of the transmembrane glycoprotein involved in thyroid-iodine uptake. Signatures were compared among cohorts using Mann-Whitney U and Kruskal-Wallis tests. Logistic regression was used for multivariate analysis.

Results: Of 445 patients analyzed, 366 were low risk and 79 were intermediate/high risk. Among 30 signatures evaluated, expression varied significantly among study cohorts in 23 (77%). Multivariate analysis demonstrated the Invasion Score signature as predictive of greater American Thyroid Association risk classification (odds ratio, 1.3; 95% confidence interval, 1.1-1.5, P = .005) whereas Sodium-Iodide Symporter Expression was protective (odds ratio, 0.78; 95% confidence interval, 0.63-0.94, P = .015).

Conclusion: Multiple signature expression profiles showed marked variation among American Thyroid Association risk classes and may help enhance preoperative prognostication. Although Invasion Score mirrors greater risk pathologic features, upregulated Sodium-Iodide Symporter Expression appears to protect from greater American Thyroid Association risk class, although further studies are needed to confirm.

分化型甲状腺癌术前预测侵袭性病理特征的分子谱验证。
背景:2015年美国甲状腺协会指南根据病理结果对分化型甲状腺癌的复发风险进行分层。侵袭性特征可能会将最初适合肺叶切除术的患者的肿瘤重新分类为中至高风险,从而保证完成甲状腺切除术。在分子通路特征的基础上,特征代表了不同的mRNA表达模式。本研究评估了分子表达谱(“特征”)是否可以术前区分高危肿瘤,并可能指导手术范围。方法:选取2017 - 2024年接受Afirma基因组测序分类器进行甲状腺结节分子检测并进行手术切除的患者。根据手术病理特征,将患者分为基于ATA指南的低风险或中/高风险队列。在评估的特征中,侵袭评分是为了排除甲状腺外扩张或广泛的血管侵袭,而碘化钠同体转运蛋白的表达反映了参与甲状腺碘摄取的跨膜糖蛋白的mRNA产生水平。使用Mann-Whitney U和Kruskal-Wallis检验比较队列间的签名。多因素分析采用Logistic回归。结果:445例患者中,366例为低危,79例为中高危。在评估的30个签名中,23个(77%)的研究队列的表达差异显著。多因素分析表明,侵袭评分标志可预测美国甲状腺相关风险分级(优势比为1.3,95%可信区间为1.1-1.5,P = 0.005),而碘化钠同体蛋白表达具有保护作用(优势比为0.78,95%可信区间为0.63-0.94,P = 0.015)。结论:多个特征表达谱在美国甲状腺协会风险等级中表现出显著差异,可能有助于增强术前预后。尽管侵袭评分反映了更大的危险病理特征,但上调的碘化钠同体转运蛋白表达似乎可以保护患者免受美国甲状腺协会更高的危险级别,尽管还需要进一步的研究来证实。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Surgery
Surgery 医学-外科
CiteScore
5.40
自引率
5.30%
发文量
687
审稿时长
64 days
期刊介绍: For 66 years, Surgery has published practical, authoritative information about procedures, clinical advances, and major trends shaping general surgery. Each issue features original scientific contributions and clinical reports. Peer-reviewed articles cover topics in oncology, trauma, gastrointestinal, vascular, and transplantation surgery. The journal also publishes papers from the meetings of its sponsoring societies, the Society of University Surgeons, the Central Surgical Association, and the American Association of Endocrine Surgeons.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信